Herceptin 400 mg Injection
Type | CANCER |
Brand Name | Roche |
Certification | FDA |
Warranty | 2 YEARS |
Male End Type | UNISEX |
Medicine Type | Allopathic |
Form | Liquid |
Strength | 400 mg |
Storage | Cool & Dry Place |
Pack Type | Vial |
Additional Information
Min. Order Quantity | 1 Box |
Port | EUROPE |
Payment Terms | T/T, Western Union, MoneyGram |
Delivery Time | 5 DAYS |
Packaging Details | ICEBOX |
Herceptin 400 mg Injection
Drug class: Antineoplastic agent
Target: HER2/neu
Other names: trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp
Elimination half-life: 2-12 days
Herceptin (chemical name: trastuzumab) can be used to treat HER2-positive breast cancer that is either early-stage or advanced-stage/metastatic.
Herceptin is currently approved by the U.S. Food and Drug Administration:
to treat metastatic HER2-positive breast cancer to stop the cancer from growing
to treat earlier stages of HER2-positive breast cancer, either as part of a regimen with chemotherapy or alone after a chemotherapy regimen that includes an anthracycline, to reduce the risk of the breast cancer coming back (recurrence)
in combination with Perjeta (chemical name: pertuzumab) and Taxotere (chemical name: docetaxel) before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal
in combination with Perjeta and chemotherapy after surgery to treat HER2-positive, early-stage breast cancer with a high risk of recurrence
Be the first to review “Herceptin 400 mg Injection”